BriaCell Other Current Assets from 2010 to 2024

BCTXW Stock  USD 0.34  0.06  18.97%   
BriaCell Therapeutics Other Current Assets yearly trend continues to be fairly stable with very little volatility. Other Current Assets will likely drop to about 721.5 K in 2024. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2008-07-31
Previous Quarter
4.6 M
Current Value
1.4 M
Quarterly Volatility
1.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 35 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of BriaCell Therapeutics Correlation against competitors.

Latest BriaCell Therapeutics' Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of BriaCell Therapeutics Corp over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. BriaCell Therapeutics' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

BriaCell Other Current Assets Regression Statistics

Arithmetic Mean747,133
Geometric Mean79,554
Coefficient Of Variation176.95
Mean Deviation876,548
Median147,734
Standard Deviation1,322,088
Sample Variance1.7T
Range5M
R-Value0.46
Mean Square Error1.5T
R-Squared0.21
Significance0.09
Slope135,416
Total Sum of Squares24.5T

BriaCell Other Current Assets History

2024721.5 K
20231.4 M
2022M
20211.3 M
2020516.9 K
2019199.7 K
2018 8123.22

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Assets1.4 M721.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.